Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Mar;62(3):483-8.

[Eradication Effect of Lansoprazole-Based Triple Therapy Against H. Pylori]

[Article in Japanese]
Affiliations
  • PMID: 15038091
Review

[Eradication Effect of Lansoprazole-Based Triple Therapy Against H. Pylori]

[Article in Japanese]
Toshiro Sugiyama et al. Nihon Rinsho. .

Abstract

Eradication of H. pylori provides a potential cure in the majority of patients with gastric ulcer as well as duodenal ulcer. Two proton pump inhibitor(PPI)-based triple therapy, combining with clarithromycin(CAM), amoxicillin(AMPC) or metronidazole have been established as standard regimens worldwide. In Japan, lansoprazole(LPZ)-based triple therapy combined with CAM and AMPC for 1 week was firstly investigated on eradication effect against H. pylori and determination of the optimal dose of CAM in multicenter, double-blind trial. Patients with active gastric ulcer or duodenal ulcer were enrolled in this study. The eradication rate of H. pylori in patients with gastric ulcer were 0%, 87.5% and 89.2% and those in patients with duodenal ulcer were 4.4%, 91.1% and 83.7% in LPZ(60 mg/d) alone, LPZ(60 mg/d) with CAM(400 mg/d) and AMPC(1,500 mg/d), LPZ(60 mg/d) with CAM(800 mg/d) and AMPC(1,500 mg/d), respectively, in the full set analysis. LPZ-based triple therapy demonstrated a high eradication rate and was safe. In addition, the combination regimens with lower or higher dose of CAM were equivalent in Japanese patients.

Similar articles

See all similar articles

Cited by 1 article

  • Helicobacter pylori infection.
    Leontiadis GI, Moayyedi P, Ford AC. Leontiadis GI, et al. BMJ Clin Evid. 2009 Oct 1;2009:0406. BMJ Clin Evid. 2009. PMID: 21718575 Free PMC article. Review.

MeSH terms

LinkOut - more resources

Feedback